These are the questions people actually search about the Wegovy pill — can I get it in the UK, is oral semaglutide as good as the injection, how does it differ from the Foundayo pill and from Rybelsus, and who can take it. Below are 15 short, factual answers, with every clinical number traced to a source at the end and single-source UK details marked as reported. The Wegovy pill is a prescription-only medicine, and a prescriber decides.
The Wegovy pill is oral semaglutide 25 mg — the same molecule as the Wegovy injection, taken once daily as a tablet.[1] In its main trial it produced an average 13.6% weight loss (treatment-policy analysis) versus 2.4% with placebo.[2] It is MHRA-approved but not yet on the NHS,[3] and it must be taken on an empty stomach with only a sip of water.[3]
The basics
1. What is the Wegovy pill?
The Wegovy pill is a once-daily tablet of oral semaglutide 25 mg for weight management in adults.[1] Semaglutide is a GLP-1 receptor agonist: it mimics the GLP-1 hormone and acts on appetite-regulating areas of the brain to increase fullness, reduce hunger and cut cravings.[3] It is the same active molecule as the Wegovy injection, just taken by mouth.[5] The MHRA approved it in the UK on 11 June 2026 as the first oral GLP-1 licensed for weight management here.[3] It is a prescription-only medicine.
2. Can I get the Wegovy pill in the UK?
It is MHRA-approved, so it can lawfully be prescribed in the UK, and UK pharmacy guidance reports private availability from around early July 2026.[9] But "available" does not mean "over the counter": it is a prescription-only medicine, so a prescriber decides whether it is suitable, and lawful supply happens only through GPhC-registered pharmacies after a consultation. It is not on the NHS at approval[3] (see question 3), and this site does not recommend or link to any provider.
3. Is the Wegovy pill available on the NHS?
Not at approval. NHS funding depends on a separate NICE technology appraisal, which is a different process from the MHRA licence.[3] One UK source reports the pill's appraisal is not expected to conclude in 2026.[10] For context, injectable semaglutide was appraised as NICE TA875, and NHS access to weight-management GLP-1s has been restricted to defined patient groups rather than offered openly — the oral form is likely to follow a similar route if recommended.[8] No completion date is confirmed, so do not assume imminent NHS access.
4. Is the Wegovy pill as good as the injection?
They contain the same active molecule, semaglutide.[5] In the OASIS 4 trial of the 25 mg tablet, average weight change was 13.6% versus 2.4% with placebo on the treatment-policy analysis, or 16.6% versus 2.7% among people who fully adhered.[2][1] Importantly, the tablet was tested against placebo, not head-to-head against the injection, so there are no like-for-like numbers to say one beats the other; choosing between them is a prescriber-led decision. Our pill vs injection guide sets out the trade-offs.
Pill vs injection, Foundayo and Rybelsus
5. Wegovy pill vs injection: what is the difference?
Same molecule, different delivery. The injection is once-weekly subcutaneous semaglutide (introduced in 2021); the pill is once-daily oral semaglutide 25 mg.[5] Because semaglutide is a peptide that stomach acid and enzymes would normally destroy, the tablet is co-formulated with an absorption enhancer called SNAC, and it only works if taken on an empty stomach with a sip of water, followed by a wait before eating.[7] The injection has no such timing rules but is given weekly by needle. The full comparison is here.
6. How is the Wegovy pill different from the Foundayo pill?
They are different medicines, and being straight with you, this site is about the Wegovy pill — so that is what we can speak to here with sources behind it. The Wegovy pill is oral semaglutide, a peptide GLP-1 made by Novo Nordisk, which is exactly why it needs the SNAC absorption enhancer and the strict on-an-empty-stomach dosing described above.[1][7] Foundayo is a separate product, and we cover it properly on our sister site foundayotablet.co.uk — for what it contains, how it is taken and its UK regulatory status, that dedicated guide is the place to look rather than this page. The practical point either way is the same: these are not interchangeable products, and — like any GLP-1 medicine for weight management — the Wegovy pill is a prescription-only medicine. A prescriber decides whether it, or any alternative, is suitable, and lawful supply in the UK happens only through GPhC-registered pharmacies against a valid prescription after a consultation.
7. Is the Wegovy pill the same as Rybelsus?
No — although both are oral semaglutide using the same SNAC absorption technology. Rybelsus is licensed only for type 2 diabetes and comes in 3, 7 and 14 mg strengths.[6] The Wegovy pill is a higher-dose product (up to 25 mg) developed for weight management.[5] They are distinct medicines with different dose ladders, so they should not be treated as interchangeable.
Taking it: how, how much, how it is dosed
8. How do you take the Wegovy pill?
Once daily, first thing on an empty stomach after fasting for at least 8 hours (usually overnight), swallowed whole with only a sip of plain water.[3] Do not crush, split or chew it.[11] Then wait at least 30 minutes before eating, drinking anything else, or taking other medicines.[3] These rules exist because absorption depends on a narrow window created by the SNAC enhancer; food or extra water in that window reduce how much semaglutide gets in.[7] Our dosage guide covers the routine in full.
9. What dose is the Wegovy pill, and how is it built up?
The maintenance (target) dose is 25 mg once daily.[1] In the UK the dose is stepped up gradually through 1.5 mg → 4 mg → 9 mg → 25 mg, with a minimum of one month at each level before increasing.[3] The slow climb is deliberate: it reduces the gastrointestinal side effects that are worst during dose increases. The prescriber sets and adjusts the dose based on response and tolerability — it is not something to change yourself. See the dosage guide for the full schedule.
10. Who can take the Wegovy pill?
It is licensed for adults, alongside a reduced-calorie diet and more physical activity. UK prescribing guidance reports the licence covers a BMI of 30 or above, or a BMI of 27–30 with at least one weight-related condition — for example type 2 diabetes, high blood pressure, raised lipids, sleep apnoea or cardiovascular disease.[9] Meeting the criteria does not mean you should take it: it is one option a prescriber may discuss, not something anyone must take, and suitability is always assessed individually against your history and other medicines (see question 11).
Safety, side effects and how well it works
11. Who should not take the Wegovy pill?
It carries a boxed warning about a risk of thyroid C-cell tumours (a semaglutide class warning based on rodent studies) and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2.[2] It is not suitable in pregnancy; UK guidance reports that, because of semaglutide's long action, women planning pregnancy should stop it at least two months beforehand.[9] Prescribers also weigh warnings around pancreatitis, gallbladder problems, dehydration and kidney injury, low blood sugar if combined with insulin or sulphonylureas, and diabetic retinopathy.[9] Screening for all of this is why a prescriber, not a website, decides suitability.
12. What are the side effects of the Wegovy pill?
Most are gut-related and typical of GLP-1 medicines: nausea, diarrhoea, vomiting, constipation, abdominal pain, indigestion, bloating, belching, headache, tiredness and dizziness.[2] In the OASIS 4 trial, gastrointestinal side effects occurred in 74% on the tablet versus 42% on placebo, and were mostly mild to moderate and worst during dose increases.[4] Discontinuation because of side effects was 7% versus 6% on placebo.[4] In the UK, suspected side effects of any medicine can be reported through the MHRA Yellow Card scheme.[12] See our full side-effects guide.
13. How much weight can you lose on the Wegovy pill?
In OASIS 4 — the 64-week trial of oral semaglutide 25 mg, published in the New England Journal of Medicine[4] — average weight change was 13.6% versus 2.4% with placebo on the treatment-policy analysis,[2] or 16.6% versus 2.7% among people who fully adhered.[1] About 76% of people lost at least 5% of their body weight, versus 31% on placebo.[2] Around one in three reached at least 20% weight loss on the adherent estimate; on the treatment-policy analysis it was 30% versus 3%.[1][4] These are trial averages; individual results vary.
14. Can I switch from the Wegovy injection to the pill?
According to UK prescribing information, people already on the 2.4 mg once-weekly injection can be transitioned directly to the 25 mg once-daily tablet.[3] Any switch should be planned and supervised by the prescriber, who will confirm the timing and check that the strict on-an-empty-stomach dosing rules for the tablet can realistically be followed each day. Do not change between products on your own.
15. Is it safe to buy the Wegovy pill online without a prescription?
No. The Wegovy pill is a prescription-only medicine: lawful UK supply happens only through GPhC-registered pharmacies against a valid prescription, after a consultation with a prescriber. Any site offering to sell it without a prescription is acting unlawfully, and what it ships cannot be assumed to be genuine, correctly dosed or safely made. The MHRA runs a #FakeMeds campaign warning about exactly this risk. If you have taken a product sold this way and feel unwell, speak to your GP or pharmacist and report it via the MHRA Yellow Card scheme.[12]
A final word
The Wegovy pill is a genuine milestone — the first oral GLP-1 licensed for weight management in the UK,[3] backed by peer-reviewed phase 3 evidence.[4] But it is a serious prescription medicine with strict dosing rules, real contraindications and common gut side effects, and it is not on the NHS at approval. Whether it is right for you is a decision for a qualified prescriber — never something to buy from an unverified website. To see what taking it involves, start with the dosage guide, then compare the tablet with the needle in pill vs injection.
References
- Novo Nordisk. Wegovy pill (oral semaglutide 25 mg) — company announcement: first oral GLP-1 for weight management, once-daily 25 mg dosing, and OASIS 4 adherent-estimand results (16.6% vs 2.7%; ~one in three reaching ≥20%). novonordisk.com
- PR Newswire. "FDA approves Novo Nordisk's Wegovy pill, the first and only oral GLP-1 for weight loss in adults" — US indication, boxed warning and contraindications (medullary thyroid carcinoma / MEN 2), common side effects, OASIS 4 treatment-policy result (13.6% vs 2.4%) and ≥5% responders (76% vs 31%) (secondary source).
- The Pharmaceutical Journal. "MHRA approves semaglutide oral tablets for weight loss" — UK licence dated 11 June 2026, mechanism, titration ladder (1.5/4/9/25 mg), administration timing, direct switch from the 2.4 mg weekly injection, and NHS/NICE status (secondary source).
- American College of Cardiology. OASIS 4 journal scan (oral semaglutide 25 mg; published in the New England Journal of Medicine, 17 September 2025) — trial design, gastrointestinal adverse events (74% vs 42%), discontinuation (7% vs 6%) and the treatment-policy ≥20% proportion (30% vs 3%) (secondary source).
- GoodRx. Rybelsus vs Wegovy — same active molecule; the injection is once-weekly subcutaneous semaglutide introduced in 2021, and the pill is once-daily oral semaglutide (secondary source).
- US Food and Drug Administration. Rybelsus (oral semaglutide) prescribing information — the 3/7/14 mg diabetes strengths and the shared SNAC oral-semaglutide administration rules. accessdata.fda.gov
- Biopharma PEG. "What is SNAC in oral semaglutide?" — why the peptide needs an absorption enhancer and strict on-an-empty-stomach timing (secondary source).
- National Institute for Health and Care Excellence. TA875 — semaglutide (injectable) for managing overweight and obesity; context for the pill's likely restricted NHS route. nice.org.uk
- UK pharmacy prescribing guidance (Wegovy pill guide) — reported UK eligibility (BMI ≥30, or 27–30 with a weight-related condition), private availability from early July 2026, the pregnancy precaution (stop ≥2 months before planned pregnancy) and warnings/precautions (single source; treat as reported).
- medino. "When will the Wegovy pill be available in the UK?" — reported that the NICE appraisal is not expected to conclude in 2026 (single source; treat as reported).
- Rightangled. Wegovy pill UK / oral semaglutide 2026 — UK guidance that the tablet should be swallowed whole and not crushed, split or chewed (single source; treat as reported).
- Medicines and Healthcare products Regulatory Agency (MHRA). Yellow Card scheme — report a suspected side effect. yellowcard.mhra.gov.uk